← Back to Search

AKI Alerts for Acute Kidney Injury

N/A
Recruiting
Led By Francis P Wilson, MD MSCE
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed at point of discharge from index hospitalization, up to one year post-randomization
Awards & highlights

Study Summary

This trial seeks to reduce AKI rates, dialysis and mortality by targeting AKI alerts to those most likely to benefit.

Who is the study for?
This trial is for adults over 18 who are hospitalized and have acute kidney injury (AKI) as shown by a significant rise in creatinine levels. It's not open to those already on dialysis, with very high initial creatinine, previous participation, hospice care, recent kidney transplant or opted out of health record research.Check my eligibility
What is being tested?
The study tests if targeting AKI alerts using uplift modeling to patients most likely to benefit can reduce the worsening of AKI, need for dialysis, or death. The alert aims to prompt timely medical response when a patient's condition indicates risk.See study design
What are the potential side effects?
Since this intervention involves an alert system rather than medication or surgery, traditional side effects are not applicable. However, there may be indirect effects related to changes in clinical management following an alert.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed from the date of randomization to the cessation of aki during index hospitalization, up to one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed from the date of randomization to the cessation of aki during index hospitalization, up to one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of patients with progression to a higher stage of AKI OR Dialysis OR Death
Secondary outcome measures
14-day Mortality
14-day dialysis
30 day readmission rate
+9 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: RecommendedExperimental Treatment1 Intervention
Those whose uplift score represents a probability of benefit greater than 0.5 will generate an alert, while those whose uplift score represents a probability of benefit less than 0.5 will not generate an alert.
Group II: Anti-recommendedExperimental Treatment1 Intervention
Those whose uplift score represents a probability of benefit greater than 0.5 will not generate an alert, while those whose uplift score represents a probability of benefit less than 0.5 will generate an alert.

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,866 Previous Clinical Trials
2,738,875 Total Patients Enrolled
9 Trials studying Acute Kidney Injury
20,950 Patients Enrolled for Acute Kidney Injury
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,378 Previous Clinical Trials
4,311,571 Total Patients Enrolled
24 Trials studying Acute Kidney Injury
22,900 Patients Enrolled for Acute Kidney Injury
Francis P Wilson, MD MSCEPrincipal InvestigatorYale University
7 Previous Clinical Trials
10,478 Total Patients Enrolled
2 Trials studying Acute Kidney Injury
8,423 Patients Enrolled for Acute Kidney Injury
~2482 spots leftby Feb 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top